Exploring the Combination of First-Line Avelumab/Axitinib in RCC

Video

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses a phase 1b trial of first-line avelumab (Bavencio) plus axitinib (Inlyta) in patients with advanced renal cell carcinoma (RCC).

Related Videos
Experts on GU Cancer
Experts on GU Cancer
Experts on GU Cancer
Experts on GU Cancer
Related Content